|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
Valuation Estimation |
EPS (Current/Estimated)
-8.73/-187.84
|
Enterprise Value
5.63M
|
Balance Sheet |
Book Value Per Share
1.65
|
Cash Flow |
Cash Flow Yield
--
|
Income Statement |
Total Revenue
0
|
Operating Revenue Per Share
3.73
|
Industry Comparison
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
Quotes are at least 15-min delayed:2024/10/31 18:39 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
|
|||
Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader. |